Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02423343
Title A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Eli Lilly and Company
Age Groups: adult
Covered Countries USA | ESP

Facility Status City State Zip Country Details
University of Alabama at Birmingham Medical Center Birmingham Alabama 35294 United States Details
University of California - San Diego La Jolla California 92093 United States Details
H Lee Moffitt Cancer Center Tampa Florida 33612-9497 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Hospital Universitari Vall d'Hebron Barcelona 08035 Spain Details
Institut Catala d'Oncologia Barcelona 08907 Spain Details
Hospital Universitario 12 de Octubre Madrid 28041 Spain Details
Hospital Regional Universitario de Málaga Malaga 29010 Spain Details
*Shaded cells indicate that there was no data available from for the field